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Abstract
Background: Green tea consumption has been shown to have cancer preventive qualities. Among the constituents of green
tea, (-)-Epigallocatechin-3-O-gallate (EGCG) is the most effective at inhibiting carcinogenesis. However, the concentrations of
EGCG that are required to elicit the anticancer effects in a variety of cancer cell types are much higher than the peak plasma
concentration that occurs after drinking an equivalent of 2–3 cups of green tea. To obtain the anticancer effects of EGCG
when consumed at a reasonable concentration in daily life, we investigated the combination effect of EGCG and food
ingredient that may enhance the anticancer activity of EGCG on subcutaneous tumor growth in C57BL/6N mice challenged
with B16 melanoma cells.
Methodology/Principal Findings: All-trans-retinoic acid (ATRA) enhanced the expression of the 67-kDa laminin receptor
(67LR) and increased EGCG-induced cell growth inhibition in B16 melanoma cells. The cell growth inhibition seen with the
combined EGCG and ATRA treatment was abolished by treatment with an anti-67LR antibody. In addition, the combined
EGCG and ATRA treatment significantly suppressed the melanoma tumor growth in mice. Expression of 67LR in the tumor
increased upon oral administration of ATRA or a combined treatment of EGCG and ATRA treatment. Furthermore, RNAi-
mediated silencing of the retinoic acid receptor (RAR) a attenuated the ATRA-induced enhancement of 67LR expression in
the melanoma cells. An RAR agonist enhanced the expression levels of 67LR and increased EGCG-induced cell growth
inhibition.
Conclusions/Significance: Our findings provide a molecular basis for the combination effect seen with dietary components,
and indicate that ATRA may be a beneficial food component for cancer prevention when combined with EGCG.
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Introduction
Tea (Camellia sinensis L.) is one of the most widely consumed
beverages in the world. (-)-Epigallocatechin-3-O-gallate (EGCG),
whichisthemajorgreenteacatechinpresentintheleaves,isbelieved
to the compound most responsible for the health benefits attributed
to tea. EGCG was reported to have antioxidative [1,2], antimuta-
genic [3], anti-inflammatory [4], and anticarcinogenic activities [5].
Although the EGCG concentrations required to elicit the
anticancer activity have been shown to be more than 1 mM, the
blood level of EGCG after consuming the equivalent of 2–3 cups
of green tea was 0.1–0.6 mM and for an equivalent of 7–9 cups was
still lower than 1 mM [6,7]. In a cohort study, daily consumption
of ten cups of green tea was required for the cancer preventive
effect [8]. Moreover, adverse effects of green tea, mainly hepatitis,
by consumption of high doses of green tea have been reported [9].
Therefore, it is important to enhance the pharmacologic effect of
EGCG to obtain the health benefit in reasonable concentration in
daily life.
We have reported that the cell-surface binding of EGCG and its
derivatives is involved in their biological activities [10–15]. We
have identified the 67-kDa laminin receptor (67LR) as a cell
surface receptor for EGCG that mediates the anticancer activity of
EGCG [16]. 67LR has been shown to be overexpressed on the cell
surface of various tumor cells [17]. It was postulated that 67LR
plays a significant role in the tumor progression and speculated
that studies conducted to define the function of 67LR could
provide a new approach to cancer prevention. Indeed, expression
of 67 LR confers EGCG responsiveness to tumor cells in vivo [18].
Vitamin A, also known as retinol, participates in physiological
activities related to the immune system, maintenance of epithelial
and mucosa tissues, growth, reproduction, and bone development.
It comes from animal sources, such as eggs, meat, milk, cheese,
cream, liver, kidney, cod and halibut fish oil. In vitro and in animal
models, it has been demonstrated that vitamin A is involved in the
regulation and promotion of growth and differentiation of many
cells [19]. The visual function of vitamin A depends on its natural
and synthetic derivatives, retinoids [20]. All-trans-retinoic acid
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documented as a growth and differentiation factor in many tissues
and cells, and proved to be an effective treatment to many diseases
including cancers [21,22].
Retinoids exert their physiological activities through retinoid
receptor nuclear proteins that belong to the superfamily of steroid/
thyroid hormone receptors, of which there are two classes, retinoic
acid receptors (RARs) and the retinoic-X receptors (RXRs), each
of which has three subtypes, a, b, and c [23,24]. The natural
ligands for the RARs are ATRA and its stereoisomers 9-cis-RA
and 13-cis-RA, whereas RXRs are activated by 9-cis-RA only.
ATRA acts through RAR to transcriptionally activate target
genes, such as cytochrome P450 and CRABI [24].
This study was designed to identify a food component that could
be effectively used in combination with EGCG and to investigate
the mechanism of action of this combination. By using in vitro and
in vivo systems involving a highly metastatic mouse B16 melanoma
cell line [25], we found that ATRA enhances the antitumor
activity of EGCG by upregulating the 67 LR expression through
RAR.
Results
ATRA enhances the 67LR expression and EGCG-induced
cell growth inhibition in B16 cells
We previously reported that ATRA enhances the expression of
67LR on MCF-7 cells [16]. To determine whether ATRA
enhances anti-tumor effect of EGCG in vivo model, we examined
the 67LR expression on B16 melanoma cells by using Western blot
analysis after treatment with different concentrations of ATRA.
ATRA enhanced the expression of 67LR in a dose dependent
manner (Fig. 1A). We also found that ATRA treatment increased
the cell surface expression of the 67LR as compared with the
expression in the control cells (Fig. 1B).
Figure 1. ATRA enhances the expression of 67LR and cell growth inhibitory activity of EGCG. A) Structure of EGCG and ATRA. B) 67LR
protein levels in B16 cells exposed to the indicated concentrations of ATRA for 48 h were analyzed by Western blot analysis. Levels of 67LR expression
were detected with anti 67LR serum, and were normalized to b-Actin. Band intensities were quantified using NIH Image J software. C) Anti-67LR
antibody conjugated with Alexa Fluor 488 (1 mg/ml) was used at a dilution of 1:100. Photographs were taken under Keyence BZ-8001 fluorescence
microscope. D) Cells were counted after treatment with or without 0.5 mM EGCG and/or 0.1 mM ATRA in DMEM supplemented with 1% FCS for 48 h
and 96 h each. Cell proliferation was evaluated by counting the number of cells using a Counlter Counter. Data shown are means 6 S.D. for three
samples. Data containing asterisk marks are significantly different from the values in control at ***p,0.001.
doi:10.1371/journal.pone.0011051.g001
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treatment on cell growth of B16 cells. Combination treatment with
ATRA (0.1 mM) and EGCG at a physiological concentration
(0.5 mM) significantly suppressed the number of B16 cells to 52.4%
of the control, whereas treatment with EGCG or ATRA alone did
not inhibit cell growth (Fig. 1C). These results suggest that ATRA
enhances EGCG-induced cell growth inhibition through 67LR
upregulation in B16 cells.
ATRA induced the cell growth inhibitory activity of EGCG
through the enhancing of EGCG binding to 67LR
Cell surface binding of EGCG was assessed using SPR
biosensor assay (Fig. 2A). We found that ATRA significantly
enhances the binding of EGCG to cells surface of B16 cells. To
investigate the participation of 67LR in ATRA-induced the cell
growth inhibitory activity of EGCG, B16 cells were treated with
an anti-67LR antibody. The growth of the cells treated with a
control antibody was inhibited by the combined EGCG and
ATRA treatment (Fig. 2B). This growth-suppressive effect was
eliminated upon treatment with an anti-67LR antibody. Together,
these observations show that ATRA action for the cell growth
inhibitory activity of EGCG is attributable to the enhancement of
cell surface binding of EGCG via 67LR.
Combined EGCG and ATRA treatment suppresses tumor
growth in vivo
To determine the in vivo efficacy and safety of the combined
treatment, mice were implanted with B16 cells and treated with
EGCG and/or ATRA. Compared to treatment with a vehicle
control, combined treatment significantly reduced the tumor
volume over the duration of the study (Fig. 3A, B, and C). The
tumor volume and weight in mice treated with EGCG or ATRA
alone did not differ from those in mice treated with the vehicle
control. On the other hand, the mean tumor weight in the
combination-treatment group was ,40% less than that in the
control group, indicating that ATRA intensifies the anti-tumor
activity of EGCG. Mice subjected to the combination treatment
lost 0.6 g of weight (data not shown). All other physiological
parameters (i.e., liver, kidney, spleen, and uterine weight) did not
show any other obvious side effects.
To examine whether 67LR are involved in the inhibition of
tumor growth, we measured the expression of 67LR in the tumor
cells by using Western blot analysis. As shown in Fig. 3D, the
67LR levels in the tumor were increased upon oral administration
ATRA, or combination of EGCG and ATRA. These results
suggest that ATRA enhances the EGCG-induced inhibition of
tumor growth through 67LR upregulation in vivo.
Enhancement of 67LR expression by ATRA is mediated
through RARa
RAR that binds to ligand ATRA form a heterodimer with
RXRs and regulate the expression of specific genes [26,27]. To
investigate whether the ATRA-induced enhancement of 67LR
expression is mediated through RARa, B16 cells were stably
transfected with RARa shRNA expression vector that allows
knockdown of RARa (Fig. 4A). Knockdown of RARa attenuated
the ATRA-induced enhancement of 67LR expression (Fig. 4B).
These results suggest that ATRA enhances 67LR expression
through RARa.
RAR agonist enhances EGCG-induced cell growth
inhibition through 67LR upregulation
To investigate the participation of RAR in ATRA-mediated
enhancement of EGCG-induced cell growth inhibition through
67LR, B16 cells were treated with the pan-RAR agonist TTNPB.
TTNPB enhanced the protein levels and cell-surface levels of
67LR after 48 h of treatment (Fig. 5A, B). Moreover, treatment
with TTNPB enhanced EGCG-induced cell growth inhibition
(Fig. 5C). The growth-suppressive effect by combination treatment
with EGCG and TTNPB was obviously reduced upon treatment
Figure 2. ATRA induces the EGCG activity through the enhancing of EGCG binding to 67LR. A) EGCG binding to the surface of B16 cells
treated with (red line) or without (black line) ATRA monitored by surface plasmon resonance. EGCG was injected at a concentration of 5 mM for the
indicated time interval (+ EGCG). B) B16 cells treated with 0.1 mM ATRA in DMEM supplemented with 1% FCS for 48 h. Then, the cells were treated
with either anti-67LR (MLuC5) or control antibody (mouse IgM) for 2 h and then the cells were added to 0.5 mM EGCG for 48 h. Cell proliferation was
assessed by the WST-1 reagent. Cell number was measured as 430 nm absorbance and shown as relative of control. Data shown are means 6 S.D. for
three samples. Data containing asterisk marks are significantly different from the values in control at ***p,0.001.
doi:10.1371/journal.pone.0011051.g002
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RAR-mediated action is involved in the ATRA-induced enhance-
ment of EGCG-elicited cell growth inhibition.
Discussion
Recent studies have suggested a causal association between high
doses of green tea-containing dietary supplements and liver
damage [9]. Laboratory study of green tea-derived preparations
in rodents has also shown revealed toxic effects at high doses [28].
In human, hepatotoxicity was reported in a 45-year-old man
following consumption of 6 cups of green tea per day for 4 months
[29]. To determine the anticancer effects of EGCG at the
concentration (0.5 mM) found in human plasma after consuming
two or three cups of green tea [6], we studied the ideal
combination of EGCG and food ingredient that may enhance
the antitumor activity of EGCG in vivo. Here, we showed that
ATRA enhanced EGCG-induced tumor growth inhibition by
upregulatiing of the 67LR in vivo.
ATRA has been used as chemopreventive and therapeutic
agents for the treatment of a wide variety of tumors [30,31,32],
especially in combination with another therapeutic agent [33].
Huang et al. have reported that ATRA intensifies rosiglitazone-
induced growth inhibition and differentiation in multiple myeloma
cells [34]. In addtion, Karmakar et al. have shown that the
combination of ATRA and paclitaxel induces cell differentiation
and apoptosis in human glioblastoma U87MG xenografts in nude
mice [35]. Therefore, ATRA may be a potent candidate for an
effective EGCG-based therapeutic combination for cancer pre-
vention. This hypothesis is supported by our previous report
Figure 3. Tumor growth and expression levels of 67LR after the treatment ATRA and EGCG in vivo. C57BL/6N mice were subcutaneosly
inoculated with B16 cells. The administration of 0.1% EGCG, ATRA (10.5 mg/kg), and combination of EGCG and ATRA was started 1 day before the
cell inoculation. A) We excised tumors from mice 22 days after cell inoculation and photographed them. B) Tumor weights are represented as
the mean 6 S.E. of five mice. Logarithmic transformation for them were analyzed using an one-way ANOVA coupled with a Dunnet test in which
*p,0.05 was the minimum requirement for a statistically significant difference from control group. C) Tumor volumes was measured in two
dimensions and calculated as follows: lengh/26width
2. Each data point represents the mean 6 S.E. of tumor volumes from five animals and they are
significantly different from control group at *p,0.05 (Mann-Whitney U test). D) Representative Western blot analyses of 67LR from each individual
mouse. Levels of these proteins expression were normalized to b-Actin. Band intensities were quantified using NIH Image J software.
doi:10.1371/journal.pone.0011051.g003
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of cancer cells [16]. In this study, we showed that a combination
treatment of EGCG and ATRA suppresses tumor growth in mice
without causing any obvious side effects.
When subjects were given a normal dose of ATRA (45 mg/m
2)
that is commonly used as therapy for leukemia, the maximum
plasma concentration of ATRA was approximately 1 mM [36].
The concentration of ATRA (0.1 mM) used in our study was much
lower than the maximum concentration in human plasma. In
consideration of these facts, the activities observed at 0.1 mM
ATRA are relevant to an in vivo situation.
Although overexpression of 67LR has been correlated with
increased aggressiveness and malignancy of some tumors
[17,37,38], our results show that the enhancement of 67LR
expression at the cell surface of melanoma cells is not associated
with the incidence and volume of tumor. These results suggest that
upregulation of 67LR alone does not correlate with the
malignancy of melanoma.
Recently, we have shown new insights into the 67LR signaling
pathway [18]. Our previous study showed that EGCG induces
dephosphorylation of MYPT1 at Thr696 and activates myosin
phosphatase through 67LR. In addition, EGCG-induced tumor
growth inhibition was abrogated by silencing of 67LR, eEF1A, or
MYPT1 in tumor cells, suggesting that the signaling pathway
mediated by 67LR, eEF1A, and MYPT1 is indispensable for the
anticancer effect of EGCG. These findings are implicated in that
the 67LR signaling pathway may be involved in the combination
of EGCG and ATRA-induced tumor growth inhibition.
This is the first report showing that 67LR expression is
regulated by RAR. The finding is supported by a previous report
showing that 37LRP, the precursor of 67LR, is upregulated in
response to RA [39]. In contrast, RA has been shown to have an
anticancer effect on leukaemic cells [40], despite the finding that
RA reduces expression of 67LR in leukaemic cells [41].
Therefore, the effect of RA on the expression of 67LR expression
is markedly depending on the cell type. It has been shown that
such opposing effects of RA are affected by the expression of
transcription factors. For example, RA activates the nuclear
receptor PPARb/c in addition to RAR. The differentia
partitioning of RA between the two receptors is regulated by
the intracellular lipid binding proteins CRABP-II and FABP5. In
cells that express a high CRABP-II/FABP5 ratio, RA is
channeled to the RAR, which often results in growth inhibition.
Conversely, in the presence of a low CRABP-II/FABP5
expression ratio, RA is targeted to PPARb/c, thereby upregulat-
ing survival pathways [42].
Our results showed that ATRA enhances 67LR expression
through RARa, thus indicating that RARa is involved in ATRA-
induced EGCG-mediated inhibition of cell growth inhibition via
67LR. Moreover, we showed that RAR agonist TTNPB enhances
the protein levels and cell-surface levels of 67LR, and EGCG-
induced cell growth inhibition. These indicate that any com-
pounds which activate RAR may be a candidate to enhance the
antitumor activity of EGCG.
The results shown in this study provide a molecular basis for the
combination effect of dietary components. More definitive
information on the cancer-preventive activity of combined EGCG
and ATRA ingestion will emerge from cohort studies and human
intervention trials.
Materials and Methods
Ethics Statement
All animal works were carried out in accordance with the law
(number 105) and notification (number 6) of the Japanese
government for the welfare of experimental animal. All procedures
were approved by the Animal Care and Use Committee of
Kyushu University.
Materials and Antibodies
EGCG was purchased from Sigma and DSM Nutritional
Products, Inc. (Parsippany, NJ). Catalase and anti-b-Actin
antibody were purchased from Sigma. Anti-67LR antibody
(MLuC5) was purchased from Abcam (ab80582) and anti-67LR
serum was obtained from the rabbit which was immunized with
synthesized peptide corresponding to residues 161–170 of human
67LR. Anti-RARa antibody was purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA). ATRA was purchased from
Sigma and was prepared as 10 mM stocks in 100% ethanol. ((E)-4-
[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylenyl)-1-propenyl]
Figure 4. ATRA enhances the 67LR expression via RARa.A ) RARa knockdown in B16 cells stably transfected with RARa shRNA expression
vector was confirmed by Western blot analysis. B) B16 cells stably transfected with the control shRNA or the RARa shRNA expression vector were
treated with or without 0.1 mM ATRA in DMEM supplemented with 1% FCS for 48 h. Levels of 67LR expression were analyzed by Western blot analysis
and were normalized to b-Actin. Band intensities were quantified using NIH Image J software.
doi:10.1371/journal.pone.0011051.g004
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was dissolved in ethanol at 10 mM. These stocks were diluted with
the media to the desired concentrations immediately before each
experiment, keeping the final concentration of ethanol at 0.1%. All
experiments were performed under low-light conditions to
minimize retinoid photoisomerization.
Cell Culture and RNA interference by short hairpin RNA
(shRNA)
Mouse melanoma B16 cells were maintained in Dulbecco’s
modified Eagle’s medium containing 5% FCS. To assess cell
proliferation, cells were treated with EGCG or ATRA for 48 h in
Dulbecco’s modified Eagle’s medium supplemented with 1% FCS,
Figure 5. RAR agonist induced EGCG-elicited cell growth inhibition through 67LR upregulation. A) Cells were treated with or without
0.1 mM ATRA or 0.1 mM TTNPB in DMEM supplemented with 1% FCS for 48 h and were analyzed by Western blot analysis. Levels of 67LR expression
were normalized to b-Actin. Band intensities were quantified using NIH Image J software. B) Anti-67 LR antibody conjugated with Alexa Fluor 488 was
used at a dilution of 1:100. Photographs were taken under Keyence BZ-8100 fluorescence microscope. C) Cells were treated with 0.1 mM ATRA or
RARa agonist, 0.1 mM TTNPB in DMEM supplemented with 1% FCS for 48 h, then treated with 0.5 mM of EGCG for 48 h. Data shown are means 6 S.D.
for three samples. Data containing asterisk marks are significantly different from the values in control at **p,0.01, ***p,0.001. D) B16 cells were
treated with 0.1 mM TTNPB in DMEM supplemented with 1% FCS for 48 h, then the cells were treated with either anti-67LR (MLuC5) or control
antibody (mouse IgM) for 2 h, and the cells were added 0.5 mM of EGCG for 48 h. Cells proliferation was assessed by the WST-1 reagent. Cell number
was measured as 430 nm absorbance and shown as relative of control. Data shown are means 6 S.D. for three samples. Data containing asterisk
marks are significantly different from the values in control at ***p,0.001.
doi:10.1371/journal.pone.0011051.g005
Enhancing EGCG Sensing by ATRA
PLoS ONE | www.plosone.org 6 June 2010 | Volume 5 | Issue 6 | e110515 mg/ml BSA, and 200 units/ml catalase. FuGene6 transfection
reagent (Roche Applied Science) was used for stable transfection of
cells, according to the manufacturer’s protocol. For selecting stable
clones, transfected cells were grown in medium containing G418
for neomycin resistance.
Anti-67LR antibody treatment for Proliferation assay
Cell proliferation was assessed by the water-soluble tetrazolium
salt (WST-1) reagent according to the manufacturer’s instructions
(Roche Molecular Biochemicals, Germany). B16 cells were treated
with ATRA or TTNPB in DMEM supplemented with 1% FCS
for 48 h. Then, the cells were treated with either anti-67LR
(MLuC5) or control antibody (mouse IgM) for 2 h and the cells
were cultured in the medium containing 0.5 mM EGCG for 48 h.
The absorbance of each well was measured at 430 nm with a
microplate reader (LS-PLATE manager 2001, Wako).
Western Blot Analysis
Cells were lysed in cell lysis buffer containing 50 mM Tris-HCl
(pH 7.5), 150 mM NaCl, 1% Triton X-100, 1 mM EDTA,
50 mM NaF, 30 mM Na4P2O7, 1 mM phenylmethanesulfonyl
fluoride, 2 mg/ml aprotinin, and 1 mM pervanadate. Proteins
were resolved on SDS-polyacrylamide gels and then transferred
onto a nitrocellulose membrane. The membranes were blocked in
2.5% BSA and incubated with the antibody, followed by
incubation with a secondary antibody. Proteins were visualized
by using the ECL Advance kit (Amersham Biosciences). Band
intensities were quantified using NIH Image-J software.
Binding analysis using surface plasmon resonance
biosensor
B16 cells were cultured with or without 1 mM ATRA for 24 h,
and were subjected to EGCG binding assay using the surface
plasmon resonance (SPR) biosensor SPR670 (Moritex Corp.,
Tokyo, Japan). The cells were immobilized on a dithiodibutyric
acid-coated sensor chip, after activation with carbodiimide
(16 mM) and N-hydroxysuccinimide (13 mM). Phosphate-buffered
saline (PBS, pH 7.4) was used as a mobile phase medium at a flow
rate of 30 ml/min at 25uC. Binding of EGCG (1 mM) to the
immobilized cells was monitored in real time by measuring
changes in resonance unit. The sensorgrams for the reference
channel (sample-free PBS) were subtracted simultaneously from
the sensorgrams for sensing channel (sample-containing PBS) on
the same sensor chip.
Fluorescent Microscope
Cells were fixed 4% paraformaldehyde in PBS pH 7.4 for
30 min on ice. And then cells were incubated with 3% BSA in PBS
for 2 h. After this blocking, Cells were incubated with 10 mg/mL
of the anti-67LR antibody conjugated with Alexa Fluor 488 for
2 hours on ice. After washing, cells were observed under the
fluorescent microscopy (KEYENCE BZ-8100).
Tumor Growth in vivo
B16 cells were detached and resuspended in phosphate-buffered
saline. 5610
5 cells in a single cell suspension were injected
subcutaneously into the back of C57BL/6N mice (Charles River
Laboratories Japan, Yokohama, Japan). They were kept at the
Biotron Institute of Kyushu University in a 12-h light/12-h dark
cycle (light on at 8 a.m.) in an air-conditioned room (20uC and
60% humidity under specific pathogen-free conditions). The mice
randomly assigned to 4 groups for treatment. Mice were treated
with EGCG, ATRA, EGCG+ATRA, or a vehicle control for 23
days. EGCG was dissolved in vehicle (0.01% ascorbic acid
solutions (pH 5.5) adjusted by NaOH). One day before inocula-
tion, drinking water bottles were replaced by 0.1% EGCG every 2
days. ATRA was dissolved in vehicle (olive oil) and administered
through oral gavage every 3 days. Dosing solutions were prepared
fresh each day. Tumor sizes were determined every other day via
caliper measurements. The tumor volume was measured in two
dimensions and calculated as follows: length/26 width
2. Each
data point represents the mean 6 S.E. of tumor volumes from 6–7
animals.
Statistical Analysis
Data for tumor growth in vivo were analyzed by a Mann-
Whitney U test. The other data were analyzed by Student’s t test.
A level of p,0.05 was considered significant.
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